New real-world evidence (RWE) presented at this year’s European Renal Association Congress explored hypokalemia care, finding that reduction or discontinuation of renin-angiotensin-aldosterone system inhibitor (RAASi) worsens outcomes of patients admitted for hyperkalemia (HK), high calcium levels in blood. RWE from the ZORA study shows that few patients have their RAASi medications reinitiated after a hyperkalemia event, which is associated with a two times increase in mortality.
According to The Pharma Letter, “Another analysis from ZORA also confirmed that patients that had reduced RAASi treatment following a HK event spent approximately nine more days in hospital compared to patients that had maintained these life-saving medicines.”
To read more, click here.
(Source: The Pharma Letter, June 19th, 2023)